Welcome to our dedicated page for Encision SEC filings (Ticker: ECIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Encision Inc. (ECIA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports and other documents filed with the U.S. Securities and Exchange Commission. Encision is a Boulder, Colorado-based medical device company that designs surgical instruments for minimally invasive procedures and owns patented Active Electrode Monitoring (AEM®) technology.
Through its filings, Encision reports details that go beyond headline financial results in press releases. Investors can review information on product and service revenue, gross margins, operating expenses, financing arrangements such as secured notes and lines of credit, and changes in shareholders’ equity. These documents help explain how Encision funds its operations, invests in research and development, and manages its capital structure over time.
Recent Form 8-K filings have disclosed corporate governance and leadership changes, including director resignations and the resignation of the company’s CEO and President, along with the appointment of an Interim President and CEO. Such filings provide context on board composition, management transitions, and the company’s stated reasons for key changes.
On Stock Titan, Encision’s filings are updated as they are made available through EDGAR, and AI-powered tools summarize the key points in plain language. Users can quickly identify items related to executive departures, board changes, financing events, and other material developments, then drill down into the full text for deeper analysis.
This page is a resource for anyone seeking to understand Encision’s regulatory history, including how management describes risks, capital needs, and strategic decisions in official filings, and how those disclosures relate to the company’s reported financial performance and technology focus.
Encision Inc. plans to deregister its common stock and stop filing regular reports with the SEC. The company announced that it intends to file a Form 15, which will start the deregistration process for its common stock.
The deregistration is expected to become effective ninety days after the Form 15 is filed. Once effective, Encision will suspend its ongoing reporting obligations, meaning investors will no longer receive quarterly and annual SEC filings. The company’s decision was disclosed in a current report and related press release.
Encision, Inc. announced that Gregory Trudel resigned from its board of directors and also stepped down as CEO, President and executive officer effective December 8, 2025. The company states that Mr. Trudel disagreed with the other board members on the future direction of the company and concluded it was best to resign, while emphasizing that, apart from this difference over future direction, his resignation did not stem from any dispute over current operations, policies or practices.
Following his departure, the board appointed long-time director Robert H. Fries as Interim President and CEO. Mr. Fries, age 77, has served on Encision’s board since 2003, is a certified public accountant (inactive), and has extensive finance and tax consulting experience with large public multinational companies, which the company cites as qualifications for his interim leadership role.
Encision Inc. (ECIA) reported an insider equity award to its chief executive officer and director, Brandon Shepard. On 11/18/2025, he received an option to buy 10,000 shares of Encision common stock at an exercise price of $0.25 per share, expiring on 02/17/2031. The award is reported as directly owned.
The option vests over time: 20% of the shares vest after the first year of service on 11/18/2026, and the remaining shares vest in 48 equal monthly installments thereafter. This filing documents the grant and outlines the vesting schedule but does not include any sales of stock.
Encision Inc. director equity grant: Director Brandon Shepard reported receiving a stock option award from Encision Inc. (ticker ECIA) on 11/18/2025. The option gives him the right to buy 10,000 shares of Encision common stock at an exercise price of $0.25 per share.
The option expires on 02/17/2031. The grant vests over time, with 33% vesting after the first year of service on 11/18/2026 and the remaining portion vesting in 36 equal installments thereafter. Following this transaction, Shepard beneficially owns 10,000 derivative securities directly.
Encision Inc. (ECIA) reported a new equity award to an executive. Vice President of Marketing Brandon Shepard received an option on 10,000 shares of Encision common stock on 11/18/2025 at an exercise price of $0.25 per share. The option expires on 02/17/2031. The award vests 20% after one year of service on 11/18/2026, with the remaining shares vesting in 48 equal installments thereafter, so the grant becomes exercisable gradually over time while he remains in service.
Encision Inc. (ECIA) reported a weaker quarter for the three months ended September 30, 2025. Total revenue was $1.53 million, down from $1.76 million a year ago, as product sales fell 10% to $1.48 million and service revenue decreased to $46,248 following a brief project suspension by a customer. Gross margin was 46% versus 47% a year earlier. The company posted a net loss of $267,833, compared with a $170,262 loss last year.
Cash declined to $71,731 from $257,433 at March 31, 2025. Working capital was $1.38 million, and current borrowings under the line of credit were $31,706 with up to $968,294 available, subject to eligible receivables. Management states there is substantial doubt about continuing as a going concern without additional financing, though a private placement on August 19, 2025 added $500,000 and increased shares outstanding to 16,879,645.
The quarter also reflected lower sales and marketing and G&A costs, offset by higher R&D. Disclosure controls were deemed not effective due to inadequate segregation of duties.
FAQ
What is the current stock price of Encision (ECIA)?
What is the market cap of Encision (ECIA)?
